238 related articles for article (PubMed ID: 22541618)
1. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
2. Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline.
Gerday S; Graff S; Moermans C; Guissard F; Paulus V; Henket M; Louis R; Schleich F
Thorax; 2023 Nov; 78(11):1138-1141. PubMed ID: 37657926
[TBL] [Abstract][Full Text] [Related]
3. Update on reslizumab for eosinophilic asthma.
Cardet JC; Israel E
Expert Opin Biol Ther; 2015; 15(10):1531-9. PubMed ID: 26372797
[TBL] [Abstract][Full Text] [Related]
4. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.
Pelaia C; Calabrese C; Vatrella A; Busceti MT; Garofalo E; Lombardo N; Terracciano R; Pelaia G
Biomed Res Int; 2018; 2018():4839230. PubMed ID: 29862274
[TBL] [Abstract][Full Text] [Related]
5. Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence.
Caminati M; Micheletto C; Norelli F; Olivieri B; Ottaviano G; Padoan R; Piacentini G; Schiappoli M; Senna G; Menzella F
Expert Opin Biol Ther; 2024; 24(1-2):15-23. PubMed ID: 38197326
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-5 and IL-5 receptor in health and diseases.
Takatsu K
Proc Jpn Acad Ser B Phys Biol Sci; 2011; 87(8):463-85. PubMed ID: 21986312
[TBL] [Abstract][Full Text] [Related]
7. Is there a Role for Anti-IL-5 Therapies in Eosinophilic Fasciitis?
Angelopoulos A; Kouverianos I; Daoussis D
Mediterr J Rheumatol; 2023 Dec; 34(4):414-417. PubMed ID: 38282929
[TBL] [Abstract][Full Text] [Related]
8. The Role of Benralizumab in Eosinophilic Immune Dysfunctions: A Case Report-Based Literature Review.
Gomes M; Mendes A; Ferreira F; Branco J; Tonin FS; Pedro ME
Case Rep Med; 2023; 2023():8832242. PubMed ID: 37138643
[TBL] [Abstract][Full Text] [Related]
9. Domestic Parasitic Infections in Patients with Asthma and Eosinophilia in Germany - Three Cases with Learnings in the Era of Anti-IL5 Treatments [Letter].
Hanif MI; Ihsan BM; Sholihah MM
J Asthma Allergy; 2023; 16():1347-1348. PubMed ID: 38152351
[No Abstract] [Full Text] [Related]
10. Continuous improvement of FEV
Michils A; Makhoul JP; Blekic N; Haccuria A; Perez-Bogerd S; Malinovschi A; Van Muylem A
Allergy; 2024 Apr; ():. PubMed ID: 38659210
[No Abstract] [Full Text] [Related]
11. Anti-interleukin-5 therapy in severe asthma.
Garcia G; Taillé C; Laveneziana P; Bourdin A; Chanez P; Humbert M
Eur Respir Rev; 2013 Sep; 22(129):251-7. PubMed ID: 23997052
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab treatment in patients with severe eosinophilic asthma.
Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P;
N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059
[TBL] [Abstract][Full Text] [Related]
13. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
14. Anti-IL5 therapy for asthma and beyond.
Mukherjee M; Sehmi R; Nair P
World Allergy Organ J; 2014; 7(1):32. PubMed ID: 25709744
[TBL] [Abstract][Full Text] [Related]
15. Biologic therapies targeting eosinophils: current status and future prospects.
Legrand F; Klion AD
J Allergy Clin Immunol Pract; 2015; 3(2):167-74. PubMed ID: 25754717
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Pavord ID; Korn S; Howarth P; Bleecker ER; Buhl R; Keene ON; Ortega H; Chanez P
Lancet; 2012 Aug; 380(9842):651-9. PubMed ID: 22901886
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.
Amini-Vaughan ZJ; Martinez-Moczygemba M; Huston DP
Curr Allergy Asthma Rep; 2012 Oct; 12(5):402-12. PubMed ID: 22875242
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
